Chris McClain, Senior Vice President, offers regional support for companies seeking high-quality source material for breakthrough allogeneic therapies.

Be The Match BioTherapies^® today announced expanded support for clients in the Northern California region. Chris McClain, Senior Vice President, will work from the San Francisco area to support an expanding client base seeking high-quality cellular source material for allogeneic therapy development and commercialization to deliver time-critical cell therapies to patients.

”Be The Match has been a leader in the supply of clinical grade allogeneic donor cells for over 30 years and has been supplying GMP compliant cellular starting material to developers of allogeneic cell therapy platforms since 2016. We could not be more excited to deepen our strategic focus on these emerging therapies and to work more closely with developers of those therapies located in the San Francisco area and on the west coast more broadly,” said Chris McClain, Senior Vice President at Be The Match BioTherapies.”

Since 2016 Be The Match BioTherapies has provided cell sourcing and supply chain management services for the development of allogeneic cell therapies. It successfully delivered its first cellular starting material for manufacture only two months after engaging with its first client. The organization is a trusted partner to over 50 cell and gene therapy developers ranging from small, start-ups to large international enterprises.

Chris McClain leads the sales and business development team for Be The Match BioTherapies. In this role, he engages with companies developing innovative, life-saving therapies that can leverage the cell sourcing, clinical research services, and outcomes tracking capabilities of the National Marrow Donor Program (NMDP) / Be The Match.

Before joining Be the Match BioTherapies, Chris was co-Founder of Nora Therapeutics, Inc., a venture-backed biopharmaceutical company developing novel therapies in areas of significant unmet medical need in reproductive health. He served as an advisory member of the University of Minnesota Office for Technology Commercialization Venture Center, a guest lecturer in the Life Sciences program at the University of Minnesota’s Carlson Graduate School of Management, a mentor to the annual MNCup startup competition, and a co-chair of Medical Alley’s Biotech Shared Interest Group. He earned his master’s in business administration and his bachelor’s in economics from the University of California, Berkeley.

Be The Match BioTherapies

Be The Match BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the industry-leading experience of the National Marrow Donor Program^®/Be The Match^® and a research partnership with the CIBMTR^® (Center for International Blood and Marrow Transplant Research^®), the organization designs solutions that advance the development of cell and gene therapies across the globe.

Be The Match BioTherapies is dedicated to accelerating patient access to life-saving cell and gene therapies by providing high-quality cellular source material from the Be The Match Registry^®, the world’s most diverse registry of more than 7 million potential blood stem cell donors. Through established relationships with apheresis, marrow collection, and transplant centers worldwide, the organization develops, onboards, trains, and manages expansive collection networks to advance cell therapies. Be The Match BioTherapies uses a proven infrastructure consisting of regulatory compliance and managed logistics experts and cell therapy supply chain case managers to successfully transport and deliver regulatory-compliant life-saving therapies across the globe. Through the CIBMTR, Be The Match BioTherapies extends services beyond the cell therapy supply chain to include long-term follow-up tracking for the first two FDA-approved CAR-T therapies.

For more information, visit www.BeTheMatchBioTherapies.com or follow Be The Match BioTherapies on LinkedIn or Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221025005019/en/